Physician profile
Rajeev Jain
NPI 1770527301
$17,723.33
in general payments reported to CMS, 2019-2025
30 companies · $5,456 in 2025
The $5,456 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $106 · 2021: $2,662 · 2022: $1,050 · 2023: $4,169 · 2024: $3,698 · 2025: $5,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $3,584 · Grant: $3,000 · Travel and Lodging: $656 · Education: $82.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $3,583.89 |
| Grant | $3,000.00 |
| Travel and Lodging | $655.92 |
| Education | $82.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,288.24 | 2025 | |
| Genzyme Corporation | $3,028.63 | 2023-2024 | |
| Lilly USA, LLC | $2,549.12 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $2,240.63 | 2020-2024 | Tremfya, Stelara |
| Abbvie INC. | $1,859.21 | 2019-2025 | |
| Pfizer INC. | $1,002.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $854.31 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $355.59 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $336.24 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Merck Sharp & Dohme LLC | $275.15 | 2019-2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.55 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $125.94 | 2023-2024 | |
| Ardelyx, INC. | $102.63 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $85.06 | 2019-2022 | |
| Covidien Lp | $77.00 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $51.95 | 2022 | |
| Braintree Laboratories, INC. | $47.90 | 2021-2023 | Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.93 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $33.85 | 2019-2021 | |
| Madrigal Pharmaceuticals | $32.51 | 2025 | Rezdiffra |
| Novo Nordisk INC | $32.27 | 2025 | Wegovy |
| Redhill Biopharma INC. | $25.97 | 2022 | |
| Endo Pharmaceuticals INC. | $16.48 | 2019 | |
| Olympus America INC. | $14.48 | 2025 | Single Use Repositionable Clip |
| Alfasigma USA, INC. | $14.37 | 2020 | |
| Aimmune Therapeutics, INC. | $13.82 | 2025 | Zenpep |
| Vivus LLC | $13.72 | 2025 | Qsymia |
| Phathom Pharmaceuticals, INC. | $6.74 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.